Search
for
Sort by
Research 31–60 of 1000+
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- A review of Janus kinase inhibitor use in scarring alopecia
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Janus kinase inhibitors for alopecia areata: A narrative review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Janus Kinase inhibitors in dermatology: a review
- The role of janus kinases in the treatment of autoimmune skin diseases
- Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future
- 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
- Janus kinase (JAK)
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Perceived Efficacy and Risks of Janus Kinase Inhibitors in Pediatric and Young Adult Alopecia Areata: A Cross‐Sectional Survey
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment